Moreover, it has been shown that reduced EAAT2 function observed in AD is associated with cognitive decline and increased amyloid β production, thus restoring EAAT2 protein function could represent a potential therapeutic approach in AD [57]. Here, SLC1A2 is linked to Alzheimer disease.